PL1746976T3 - Liposomy przydatne w systemie podawania leków - Google Patents

Liposomy przydatne w systemie podawania leków

Info

Publication number
PL1746976T3
PL1746976T3 PL05745505T PL05745505T PL1746976T3 PL 1746976 T3 PL1746976 T3 PL 1746976T3 PL 05745505 T PL05745505 T PL 05745505T PL 05745505 T PL05745505 T PL 05745505T PL 1746976 T3 PL1746976 T3 PL 1746976T3
Authority
PL
Poland
Prior art keywords
drying system
liposomes useful
liposomes
useful
drying
Prior art date
Application number
PL05745505T
Other languages
English (en)
Inventor
Keelung Hong
Daryl C. Drummond
Dmitri B. Kirpotin
Original Assignee
Merrimack Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1746976(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals, Inc. filed Critical Merrimack Pharmaceuticals, Inc.
Publication of PL1746976T3 publication Critical patent/PL1746976T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
PL05745505T 2004-05-03 2005-05-02 Liposomy przydatne w systemie podawania leków PL1746976T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56792104P 2004-05-03 2004-05-03

Publications (1)

Publication Number Publication Date
PL1746976T3 true PL1746976T3 (pl) 2017-09-29

Family

ID=35320018

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05745505T PL1746976T3 (pl) 2004-05-03 2005-05-02 Liposomy przydatne w systemie podawania leków

Country Status (23)

Country Link
US (22) US8147867B2 (pl)
EP (3) EP3173073B1 (pl)
JP (3) JP4971142B2 (pl)
KR (4) KR101462819B1 (pl)
CN (3) CN107811971B (pl)
AU (1) AU2005240131C1 (pl)
CA (4) CA2821167C (pl)
CY (1) CY2025003I2 (pl)
DK (1) DK1746976T3 (pl)
ES (2) ES2616047T3 (pl)
FI (2) FI3173073T3 (pl)
FR (1) FR17C1027I2 (pl)
HU (2) HUE068934T2 (pl)
LT (2) LT3173073T (pl)
LU (1) LUC00026I2 (pl)
NL (1) NL300885I2 (pl)
NO (2) NO345218B1 (pl)
PL (1) PL1746976T3 (pl)
PT (1) PT1746976T (pl)
RU (2) RU2574926C9 (pl)
TW (1) TWI359029B (pl)
UA (1) UA86063C2 (pl)
WO (1) WO2005107712A1 (pl)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
PL1746976T3 (pl) * 2004-05-03 2017-09-29 Merrimack Pharmaceuticals, Inc. Liposomy przydatne w systemie podawania leków
GEP20094620B (en) * 2004-06-01 2009-02-25 Yakult Honsha Kk Irinotecan preparation
EP1796689A4 (en) * 2004-09-20 2009-01-14 British Columbia Cancer Agency GEMCITABINE FREE OR ENCAPSULATED IN LIPOSOMES ONLY OR IN ASSOCIATION WITH FREE IDARUBICIN OR ENCAPSULATED IN LIPOSOMES
EP1807051A2 (en) * 2004-11-05 2007-07-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
US20090148506A1 (en) * 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
DE102006015271A1 (de) * 2006-04-01 2007-10-11 Lohmann & Rauscher Gmbh & Co. Kg Biguanidhaltige Liposomen
WO2008008523A1 (en) * 2006-07-14 2008-01-17 Regents Of The University Of Minnesota COMPOUNDS THAT BIND α5β1 INTEGRIN AND METHODS OF USE
US20080118500A1 (en) * 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
FR2910812B1 (fr) * 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
JP5515075B2 (ja) * 2007-01-18 2014-06-11 国立大学法人 千葉大学 微粒子製剤
AU2008227852B2 (en) * 2007-03-19 2011-02-24 Fresenius Kabi Oncology Ltd. Proliposomal and liposomal compositions
US20100173014A1 (en) * 2007-05-24 2010-07-08 Nanosolutions, Llc Methods of making and using nano scale particles
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
JP2011508780A (ja) * 2008-01-04 2011-03-17 ケラー，ブライアン，チャールズ 抗真菌薬の増強された送達
CN101536981B (zh) * 2008-03-19 2010-11-17 上海医药工业研究院 一种盐酸可乐定多囊脂质体及其制备方法
WO2009138806A1 (en) * 2008-05-13 2009-11-19 Dendrigen S.A. Novel liposome cocktail formulations containing doxorubicin and the potent multidrug resistance inhibitor amiodarone
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
US8790691B2 (en) 2008-05-23 2014-07-29 The University Of British Columbia Modified drugs for use in liposomal nanoparticles
EP2331092B1 (en) 2008-08-21 2014-03-19 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
CN101565384B (zh) * 2008-12-23 2012-12-26 南开大学 环糊精修饰单层石墨及其超分子复合物和制备方法及用途
EP2210589B1 (en) * 2009-01-22 2015-05-06 Ludwig-Maximilians-Universität München Vesicular phospholipid gels comprising proteinaceous substances
JP5588619B2 (ja) * 2009-03-11 2014-09-10 一丸ファルコス株式会社 ｐＨ応答性リポソーム
PL2415470T3 (pl) * 2009-03-30 2016-12-30 Kompozycja liposomowa
JP5622719B2 (ja) * 2009-03-30 2014-11-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
JP5392707B2 (ja) * 2009-03-31 2014-01-22 株式会社Ｎｔｔドコモ 膜小胞分裂システム
SG176571A1 (en) * 2009-05-19 2012-01-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
MX2012005775A (es) * 2009-12-03 2012-06-13 Shanghai Hengrui Pharm Co Ltd Liposoma de irinotecano o su clorhidrato y metodo para la preparacion de los mismos.
KR101000358B1 (ko) 2010-04-29 2010-12-13 서울대학교산학협력단 인테그린 αⅤβ３ 결합성 지질 유도체 및 그를 포함하는 지질 나노입자
CA2798273A1 (en) 2010-05-04 2011-11-10 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
CN107261110A (zh) * 2010-06-19 2017-10-20 健康科学西部大学 Peg化脂质体包封的糖肽抗生素的新制剂
EP3449856B1 (en) 2010-10-25 2023-06-28 Medtronic Ardian Luxembourg S.à.r.l. Device for evaluation and feedback of neuromodulation treatment
WO2012101587A1 (en) * 2011-01-28 2012-08-02 Koninklijke Philips Electronics N.V. Carriers for the local release of hydrophilic prodrugs
CA2834353A1 (en) * 2011-04-26 2012-11-01 Cedars-Sinai Medical Center Liposomal vancomycin for the treatment of mrsa infections
US8747891B2 (en) 2011-05-10 2014-06-10 The Penn State Research Foundation Ceramide anionic liposome compositions
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
CN102805729A (zh) * 2011-06-03 2012-12-05 齐鲁制药有限公司 一种长春氟宁脂质体制剂及其制备方法
CA2868516A1 (en) 2012-04-02 2013-10-10 Merrimack Pharmaceuticals, Inc. Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
AU2013249307B2 (en) 2012-04-17 2017-11-09 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
KR101949125B1 (ko) 2012-07-04 2019-02-18 고려대학교 산학협력단 ｐＨ 민감성 형광 발광의 폴리디아세틸렌 리포좀 및 이를 포함하는 약물 전달체
WO2014025042A1 (ja) * 2012-08-10 2014-02-13 大鵬薬品工業株式会社 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
EP3470061A1 (en) 2012-11-20 2019-04-17 Spectrum Pharmaceuticals, Inc. Improved method for the preparation of a dosage of liposome encapsulated vincristine for therapeutic use
KR102310786B1 (ko) 2013-02-01 2021-10-12 존원 파마, 인코포레이티드 리포좀 내로 난수용성 약물의 원격 부하
WO2014138278A1 (en) 2013-03-05 2014-09-12 The Regents Of The University Of California Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
US10220095B2 (en) 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
WO2014145187A1 (en) * 2013-03-15 2014-09-18 Taiwan Liposome Company, Ltd. Controlled drug release liposome composition
US20160051526A1 (en) * 2013-04-09 2016-02-25 Cresset Biomolecular Discovery Ltd The Local Treatment of Inflammatory Ophthalmic Disorders
ES2822584T3 (es) 2013-05-03 2021-05-04 Univ California Inducción de dinucleótidos cíclicos del interferón tipo I
SG11201601625UA (en) 2013-09-11 2016-04-28 Glenn Abrahmsohn Hypertonic antimicrobial therapeutic compositions
WO2015061592A1 (en) * 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
US9592198B2 (en) * 2013-10-28 2017-03-14 University Of Maryland, College Park Microfluidic liposome synthesis, purification and active drug loading
CA2939916A1 (en) 2014-02-18 2015-08-27 Glenn Abrahmsohn Compositions and methods for pain relief without numbness
HRP20202030T1 (hr) * 2014-04-30 2021-02-19 Fujifilm Corporation Liposomska kompozicija i postupak za njeno dobivanje
JP6276847B2 (ja) * 2014-04-30 2018-02-07 富士フイルム株式会社 リポソーム組成物及びその製造方法
EP3138557B1 (en) 2014-04-30 2023-06-07 FUJIFILM Corporation Liposome composition and method for producing same
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
AU2015301234A1 (en) * 2014-08-04 2017-06-15 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
WO2016048242A1 (en) * 2014-09-24 2016-03-31 Nanyang Technological University Sustained timolol maleate delivery from liposomes for glaucoma therapy and ocular hypertension
HK1245133A1 (zh) 2014-12-09 2018-08-24 Ipsen Biopharm Ltd. 用伊立替康脂质体治疗乳腺癌
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
US9931298B2 (en) * 2015-05-26 2018-04-03 Comfort Care For Animals Llc Liposome loading
US9855216B2 (en) * 2015-05-27 2018-01-02 Ghasem Amoabediny Targeted nano-liposome co-entrapping anti-cancer drugs
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
RU2760185C2 (ru) 2015-08-20 2021-11-22 Ипсен Биофарм Лтд. Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
TWI778942B (zh) 2015-08-21 2022-10-01 英商益普生生物製藥有限公司 使用包含微脂伊立替康（ｉｒｉｎｏｔｅｃａｎ）及奧沙利鉑（ｏｘａｌｉｐｌａｔｉｎ）之組合療法治療轉移性胰臟癌的方法
US11260126B2 (en) * 2015-08-21 2022-03-01 University Of Otago Acoustic driven drug delivery systems
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
EP3349731B1 (en) 2015-09-16 2023-11-01 Board of Regents, The University of Texas System Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer
JP6924431B2 (ja) * 2015-10-13 2021-08-25 株式会社ケーナインラボ ヒトを除く哺乳動物への薬剤の投与方法
CN105153339B (zh) * 2015-10-13 2017-10-24 浙江大学 一种氧化响应去正电荷的阳离子聚合物、制备方法和应用
EP4647126A3 (en) 2015-10-16 2026-02-11 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
US20170319573A1 (en) * 2015-10-16 2017-11-09 Ipsen Biopharm Ltd. Stabilizing Camptothecin Pharmaceutical Compositions
JP6564873B2 (ja) * 2015-11-02 2019-08-21 富士フイルム株式会社 リポソーム組成物およびその製造方法
CN108348538B (zh) * 2015-11-02 2021-06-22 富士胶片株式会社 包含吉西他滨脂质体组合物的肿瘤治疗药及试剂盒
US10751306B2 (en) 2015-11-06 2020-08-25 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
JP7017018B2 (ja) 2015-11-10 2022-02-08 チルドレンズ リサーチ インスティテュート、チルドレンズ ナショナル メディカル センター エキノマイシン製剤、その製造法および使用法
CN105287264B (zh) * 2015-11-25 2018-06-19 上海赢嘉实业有限公司 一种包封芳香油复合物的脂质体的制备方法和用途
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
CN105496992A (zh) * 2015-12-08 2016-04-20 青岛正大海尔制药有限公司 氨溴索沙丁胺醇脂质固体分散体
WO2017120537A1 (en) * 2016-01-08 2017-07-13 The Regents Of The University Of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
WO2017123616A1 (en) * 2016-01-11 2017-07-20 Merrimack Pharmaceuticals, Inc. Inhibiting b-cell lymphoma 2 (bcl-2) and related proteins
KR102461219B1 (ko) 2016-01-11 2022-10-31 메리맥 파마슈티컬즈, 인크. 혈관확장성 운동실조증 및 Rad3-관련 단백질(ATR)의 억제
CA3014616A1 (en) * 2016-02-15 2017-08-24 Kemin Industries, Inc. Water soluble lipophilic materials
US11517539B2 (en) * 2016-02-15 2022-12-06 University Of Georgia Research Foundation, Inc. IPA-3-loaded liposomes and methods of use thereof
WO2017161067A1 (en) 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions
CA3016383A1 (en) 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
WO2017192785A1 (en) 2016-05-03 2017-11-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to induce tolerance
MA45046A (fr) * 2016-05-18 2019-03-27 Ipsen Biopharm Ltd Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules
US9655847B1 (en) * 2016-07-18 2017-05-23 National Guard Health Affairs Therapeutic liposome and method of treating a subject having cancer
US10517823B1 (en) 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
US10583083B1 (en) 2016-08-10 2020-03-10 Verily Life Sciences Llc ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
CN120939250A (zh) 2016-08-12 2025-11-14 L.E.A.F.控股集团公司 聚谷氨酸化抗叶酸剂及其用途
US20180236098A1 (en) 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
KR102752868B1 (ko) * 2016-08-31 2025-01-09 큐피가부시키가이샤 난황 인지질 조성물 및 그 제조 방법, 그리고 그 난황 인지질 조성물을 사용한 지방 유제 및 리포화 제제
US11033520B2 (en) 2016-09-09 2021-06-15 Irisys, Inc. Liposomal anticancer compositions
US11071726B2 (en) 2016-11-02 2021-07-27 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
US10800817B2 (en) * 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
RU2765736C2 (ru) * 2017-01-18 2022-02-02 Темасек Лайф Сайенсиз Лаборатори Лимитед Гиперстабилизированные липосомы, повышающие направленное таргетирование митотических клеток
WO2018218052A1 (en) * 2017-05-24 2018-11-29 Northwestern University Nanoparticle-lipid composite carriers and uses thereof
CN108926719B (zh) * 2017-05-25 2020-09-01 北京格瑞特森生物医药科技有限公司 用c(RGD-ACP-K)修饰的长循环脂质体
CN110998955B (zh) * 2017-09-12 2023-04-25 奥加诺株式会社 电解液的精制装置和精制方法
WO2019054220A1 (ja) * 2017-09-12 2019-03-21 オルガノ株式会社 電解液の精製装置および精製方法
CN108047494B (zh) * 2017-11-15 2019-11-08 四川大学 植酸铵盐阻燃剂及其制备方法和用以制备的阻燃增韧聚乳酸材料
CN109364025A (zh) * 2017-11-17 2019-02-22 和龙 脂质体组合物、其制备方法及其应用
EP3735250A4 (en) 2018-01-01 2022-04-13 The Regents Of The University Of California INDUSTRIAL-SCALE SYNTHESIS OF SILICASOMES-TYPE NANOSUPPORTS
CA3090384A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
EP3749316A4 (en) 2018-02-07 2021-10-27 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF
EP3749311A4 (en) * 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
JP7487107B2 (ja) 2018-02-07 2024-05-20 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化葉酸代謝拮抗薬およびその使用
EP3749315A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED RALTITREXED AND USES THEREOF
EP3749312A4 (en) * 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
WO2019157138A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
US12336994B2 (en) 2018-02-07 2025-06-24 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
US12239734B2 (en) 2018-02-07 2025-03-04 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
CA3090509A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated methotrexate and uses thereof
US12048767B2 (en) * 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
CA3090875A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
CA3090992A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
WO2019160733A1 (en) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
WO2019160732A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
CN112334140A (zh) 2018-06-20 2021-02-05 富士胶片株式会社 包含内含吉西他滨的脂质体组合物及免疫检查点抑制剂的组合医药
FI3811931T3 (fi) * 2018-06-20 2024-09-12 Fujifilm Corp Liposomikoostumukseen kapseloidun lääkkeen ja immuunitarkistuspisteinhibiittorin sisältävä yhdistelmälääkitys
WO2020023436A1 (en) * 2018-07-23 2020-01-30 Campbell Robert B Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy
WO2020023445A1 (en) 2018-07-24 2020-01-30 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof
US12005142B2 (en) 2018-08-02 2024-06-11 Taiwan Liposome Co., Ltd. Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
WO2020033195A1 (en) * 2018-08-08 2020-02-13 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof
EP3861987A4 (en) * 2018-10-01 2021-09-15 FUJIFILM Corporation COMBINATION DRUG CONTAINING A LIPOSOME COMPOSITION ENCAPSULATING A DRUG AND A PLATINUM PREPARATION
TWI767149B (zh) * 2018-10-17 2022-06-11 台灣微脂體股份有限公司 含有免疫調節劑的緩釋藥物組合物及其用途
US20220018060A1 (en) * 2018-11-15 2022-01-20 The Regents Of The University Of California Vesicle-coated fibers and methods of making and using
CN109528654B (zh) * 2018-12-14 2021-04-23 沈阳药科大学 一种盐酸伊立替康和盐酸阿霉素共载脂质体及其制备方法
CN109528655A (zh) * 2018-12-18 2019-03-29 沈阳药科大学 一种双载药脂质体及其制备和应用
CN114127267A (zh) 2019-02-28 2022-03-01 Sqz生物技术公司 向pbmc递送生物分子以改变免疫应答
CA3136296A1 (en) 2019-04-08 2020-10-15 Sqz Biotechnologies Company Cartridge for use in a system for delivery of a payload into a cell
WO2020242996A1 (en) * 2019-05-28 2020-12-03 Nevakar Inc. Vancomycin liposome compositions and methods
US12496275B2 (en) 2019-06-17 2025-12-16 Mayo Foundation For Medical Education And Research Drug delivery methods and compositions
EP3753549A1 (en) * 2019-06-20 2020-12-23 InnoMedica Holding AG Liposomal doxorubicin formulation, method for producing a liposomal doxorubicin formulation and use of a liposomal doxorubicin formulation as a medicament
CN114144198A (zh) * 2019-07-16 2022-03-04 科斯塔治疗公司 膜脂包覆的纳米颗粒的制备方法
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US20230139328A1 (en) * 2020-03-12 2023-05-04 Aphios Corporation Dosage forms for improving organ transplantation, graft versus host disease and stem cells transplants
CA3183397A1 (en) 2020-06-18 2021-12-23 Daryl C. Drummond Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
EP4178543A1 (en) * 2020-07-07 2023-05-17 Thermosome Gmbh Liposome formulations
CN112190715B (zh) * 2020-10-21 2022-09-30 中国人民解放军军事科学院军事医学研究院 纳米药物、其制备方法及医药应用
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
US11058637B1 (en) * 2020-11-25 2021-07-13 King Abdulaziz University Surface-modified emulsomes for intranasal delivery of drugs
WO2022153211A1 (en) 2021-01-13 2022-07-21 Sun Pharma Advanced Research Company Limited Liposomal composition of a camptothecin derivative
WO2022171777A1 (en) 2021-02-12 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for prognosis and treating a patient suffering from cancer
US12447163B2 (en) * 2021-07-16 2025-10-21 Jazz Pharmaceuticals Therapeutics, Inc. Liposomal formulations of Bcl inhibitors
WO2023029041A1 (zh) * 2021-09-06 2023-03-09 北京茵诺医药科技有限公司 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法
WO2023051799A1 (zh) * 2021-09-30 2023-04-06 上海济煜医药科技有限公司 一种酒石酸长春瑞滨脂质体及其原料组合物、制备方法和应用
EP4169928A1 (en) * 2021-10-25 2023-04-26 Sandoz Ag Process for the preparation of sucrose octasulfate octakistriethylammonium salt (tasos) powder and uses thereof
CN114099691A (zh) * 2021-11-22 2022-03-01 京东方科技集团股份有限公司 一种人造细胞及其制备方法
JP2024546984A (ja) 2021-12-15 2024-12-26 イミュニクス ファーマ リミテッド 好中球エキソサイトーシス阻害剤
CN114306243B (zh) * 2022-01-07 2023-03-28 中国人民解放军空军军医大学 一种靶向梭型柔性脂质体水凝胶及其制备方法和应用
CN114469865B (zh) * 2022-03-17 2023-09-22 中国医学科学院输血研究所 一种与血细胞膜结合的脂质体药物载体及其制备方法和用途
WO2023190709A1 (ja) * 2022-03-31 2023-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物およびリポソームを含む医薬組成物
CN119562806A (zh) 2022-05-25 2025-03-04 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及其使用方法
US12194037B2 (en) * 2023-01-06 2025-01-14 Microneb Tech Holdings, Inc. Apparatus, methods, and systems for providing pharmaceutical compositions and administering medications to patients
WO2024199424A1 (zh) * 2023-03-30 2024-10-03 上海济煜医药科技有限公司 一种磷脂组合物及其制备方法及含氮化合物的应用
CN116687861A (zh) * 2023-06-07 2023-09-05 上海其胜生物制剂有限公司 一种具有细胞调节功能的大尺寸脂质体及其制备方法与应用
CN116602923A (zh) * 2023-07-20 2023-08-18 暨南大学附属第一医院（广州华侨医院） 一种用于关节炎治疗的靶向仿生纳米治疗载体系统

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
ES473087A1 (es) * 1977-09-06 1979-04-16 Studiengesellschaft Kohle Mbh Procedimiento para la preparacion de eritrocitos intactos modificados.
US4192869A (en) * 1977-09-06 1980-03-11 Studiengesellschaft Kohle Mbh. Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles
US4397846A (en) 1981-05-15 1983-08-09 Murray Weiner Storage-stable lipid vesicles and method of preparation
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL72420A (en) 1983-07-22 1987-10-30 Hoffmann La Roche Aqueous vitamin e solutions and their manufacture
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4755388A (en) 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
DE3634392A1 (de) 1986-10-09 1988-04-14 Knoll Ag Verwendung polysulfatierter niedermolekularer dextransulfate
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5043165A (en) * 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5618798A (en) * 1989-04-20 1997-04-08 Bar-Shalom; Daniel Use of sucralfate to treat baldness
ZA902710B (en) 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
DK0592446T3 (da) 1991-07-03 1996-01-29 Nexstar Pharmaceuticals Inc Fyldningsteknik til fremstilling af lægemiddelholdige liposomer
US5281237A (en) 1992-09-25 1994-01-25 Gimpelson Richard J Surgical stitching device and method of use
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4320597A1 (de) 1993-06-22 1995-01-05 Heinz C Prof Dr Dr Schroeder Verwendung von Polyphosphaten zur antiviralen Therapie und als Immunmodulatoren
US6743917B2 (en) * 1993-06-30 2004-06-01 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5538954A (en) * 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
GB9323588D0 (en) 1993-11-16 1994-01-05 Cortecs Ltd Hydrophobic preparation
EP0744939B1 (en) * 1994-02-04 2002-09-25 Lipocore Holding AB Bilayer preparations made from digalactosyldiacylglycerol containing galactolipid
US6312719B1 (en) 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US6110481A (en) * 1994-03-04 2000-08-29 Trustees Of The Stevens Institute Of Technology Controlled release device based on aqueous-organic partitioning in porous membranes
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
GB9424902D0 (en) 1994-12-09 1995-02-08 Cortecs Ltd Solubilisation Aids
AU4981896A (en) 1995-02-14 1996-09-04 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering liposome-loadable drugs
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
EP0787716B1 (en) 1996-01-31 1999-12-08 Nisshin Flour Milling Co., Ltd. Isoprene derivatives
DE19605024A1 (de) * 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
CA2252055C (en) 1996-04-11 2007-01-16 The University Of British Columbia Fusogenic liposomes
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0949906A4 (en) 1996-10-22 2004-11-24 Hermes Biosciences Inc LIPOSOMES LOADED WITH ACTIVE SUBSTANCE AND THEIR PRODUCTION METHOD
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
EP0944311B1 (en) 1996-11-19 2006-03-01 Georgetown University Method for antagonizing HEREGUlin or its receptor and use for the inhibition of cancer cells
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6939570B1 (en) * 1997-05-15 2005-09-06 University Of Washington Composition and methods for treating Alzheimer's disease and other amyloidoses
US6063400A (en) 1997-07-02 2000-05-16 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
US6316612B1 (en) 1997-08-22 2001-11-13 Ribozyme Pharmaceuticals, Inc. Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
US6083923A (en) 1997-10-31 2000-07-04 Isis Pharmaceuticals Inc. Liposomal oligonucleotide compositions for modulating RAS gene expression
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
RU2130771C1 (ru) * 1998-06-01 1999-05-27 Автушенко Сергей Сергеевич Способ получения липосомальных препаратов
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
AU1678900A (en) 1998-08-11 2000-03-06 All India Institute Of Medical Sciences A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
EP1105098B8 (en) 1998-08-12 2007-10-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal therapeutic compositions an ammonium sulphate gradient prepared using
EP1121102B1 (en) 1998-09-16 2003-04-23 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US6291676B1 (en) * 1999-03-03 2001-09-18 University Of Kentucky Research Foundation Water-soluble derivatives of camptothecin/homocamptothecin
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
ATE259231T1 (de) * 1999-04-29 2004-02-15 Alza Corp Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US20020049176A1 (en) * 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
US7025988B2 (en) * 2000-02-04 2006-04-11 Lipoxen Technologies Limited Liposomes
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
PT1286671E (pt) 2000-05-15 2006-08-31 Univ Arkansas Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan
US7060828B2 (en) 2000-06-30 2006-06-13 Inex Pharmaceuticals Corporation Liposomal camptothecins and uses thereof
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
AU2002225878A1 (en) 2000-11-02 2002-05-15 Smith Kline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
US20030064948A1 (en) 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
IL158160A0 (en) * 2001-03-26 2004-03-28 Alza Corp Liposome composition for improved intracellular delivery of a therapeutic agent
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
IL161187A0 (en) * 2001-10-03 2004-08-31 Celator Technologies Inc Liposome compositions containing metal ions and therapeutic agents
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ITBO20010610A1 (it) * 2001-10-05 2003-04-05 Haworth S P A Dispositivo per la connessione di gambe ad elementi di arredamento, ed elemento di arredamento comprendente tale dispositivo
PT1443900E (pt) 2001-11-13 2012-08-01 Celator Pharmaceuticals Inc Composições de veículo lipídico com estabilidade melhorada no sangue
US20030129224A1 (en) * 2001-11-13 2003-07-10 Paul Tardi Lipid carrier compositions and methods for improved drug retention
US20030220284A1 (en) * 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
CA2488230C (en) 2002-04-29 2013-04-09 Yves Claude Nicolau Inositol pyrophosphates, and methods of use thereof
CA2486007C (en) 2002-05-15 2011-11-22 California Pacific Medical Center Delivery of nucleic acid-like compounds
AU2003245160B2 (en) 2002-06-28 2009-09-24 Arbutus Biopharma Corporation Method and apparatus for producing liposomes
US20040243101A1 (en) * 2002-07-02 2004-12-02 Gillis Edward M. Minimally invasive drug delivery catheter
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
AR036316A1 (es) 2002-08-29 2004-08-25 Monte Verde S A Una composicion farmaceutica de liposomas de tamano pequeno y metodo de preparacion
DE10242367A1 (de) 2002-09-12 2004-03-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Thermolabiles Liposom mit geregelter Freigabetemperatur
AU2003295954A1 (en) 2002-11-26 2004-06-18 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
US20060222694A1 (en) 2003-06-27 2006-10-05 Oh Choon K Stabilized topotecan liposomal composition and methods
JP2007528854A (ja) * 2003-07-09 2007-10-18 カリフォルニア パシフィック メディカル センター 細胞への物質送達の遠隔検出
KR20070057701A (ko) 2004-03-17 2007-06-07 토카이 유니버시티 에듀케이셔널시스템 면역응답 시스템을 이용한 약물전달 시스템
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
PL1746976T3 (pl) * 2004-05-03 2017-09-29 Merrimack Pharmaceuticals, Inc. Liposomy przydatne w systemie podawania leków
GEP20094620B (en) 2004-06-01 2009-02-25 Yakult Honsha Kk Irinotecan preparation
KR20070057767A (ko) 2004-06-15 2007-06-07 앤드류 셴 천 인지질 조성물 및 이의 제조 및 사용 방법
ES2531425T3 (es) * 2004-10-05 2015-03-13 Genzyme Corp Cánula escalonada
US20060129126A1 (en) * 2004-11-19 2006-06-15 Kaplitt Michael G Infusion device and method for infusing material into the brain of a patient
US20060127467A1 (en) 2004-12-14 2006-06-15 Watkin Kenneth L Nanoparticles for delivery of therapeutic agents using ultrasound and associated methods
EP2289535B8 (en) * 2004-12-21 2018-08-08 MUSC Foundation for Research Development Compositions and methods for promoting wound healing and tissue regeneration
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2007050784A2 (en) 2005-10-25 2007-05-03 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
US20090148506A1 (en) 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
KR20080110681A (ko) 2006-04-20 2008-12-18 암겐 인코포레이티드 안정적 에멀젼 조제물
GB0614835D0 (en) 2006-07-26 2006-09-06 Isis Innovation Formation of bilayers of amphipathic molecules
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
WO2009097011A1 (en) 2007-08-17 2009-08-06 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
CA2700810A1 (en) 2007-09-28 2009-04-02 Universitatsspital Basel Immunoliposomes for treatment of cancer
WO2009059449A1 (en) 2007-11-05 2009-05-14 Celsion Corporation Novel thermosensitive liposomes containing therapeutic agents
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2016168451A1 (en) 2015-04-14 2016-10-20 Merrimack Pharmaceuticals, Inc. Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
RU2760185C2 (ru) 2015-08-20 2021-11-22 Ипсен Биофарм Лтд. Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
US20180110771A1 (en) 2016-10-21 2018-04-26 Ipsen Biopharm Ltd. Liposomal Irinotecan Preparations
EP4647126A3 (en) 2015-10-16 2026-02-11 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
US11071726B2 (en) * 2016-11-02 2021-07-27 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)

Also Published As

Publication number Publication date
US10350201B2 (en) 2019-07-16
KR20130032401A (ko) 2013-04-01
EP1746976A4 (en) 2010-09-29
RU2011112461A (ru) 2012-10-10
US9730891B2 (en) 2017-08-15
US20160095852A1 (en) 2016-04-07
US20170079914A1 (en) 2017-03-23
US20170079912A1 (en) 2017-03-23
JP2007536247A (ja) 2007-12-13
LTC3173073I2 (pl) 2025-05-12
US20160081928A1 (en) 2016-03-24
CA3006109A1 (en) 2005-11-17
NO20065532L (no) 2006-12-13
CY2025003I1 (el) 2025-07-04
CN103948545A (zh) 2014-07-30
WO2005107712A1 (en) 2005-11-17
LUC00026I2 (pl) 2017-09-08
RU2574926C9 (ru) 2020-06-16
US20170079913A1 (en) 2017-03-23
EP3173073A1 (en) 2017-05-31
US20160030342A1 (en) 2016-02-04
CN1980637A (zh) 2007-06-13
AU2005240131B2 (en) 2011-03-03
EP4218730A1 (en) 2023-08-02
JP5665950B2 (ja) 2015-02-04
FIC20250005I1 (fi) 2025-01-20
DK1746976T3 (en) 2017-04-10
US20160338956A1 (en) 2016-11-24
UA86063C2 (ru) 2009-03-25
HK1252167A1 (zh) 2019-05-17
KR101462825B1 (ko) 2014-11-21
US20130122081A1 (en) 2013-05-16
FI3173073T3 (fi) 2024-12-09
FR17C1027I2 (fr) 2020-09-04
CN107811971B (zh) 2021-10-29
RU2424792C2 (ru) 2011-07-27
KR101462819B1 (ko) 2014-11-21
US9717723B2 (en) 2017-08-01
FR17C1027I1 (pl) 2017-09-08
TW200605908A (en) 2006-02-16
EP1746976B1 (en) 2017-01-11
PT1746976T (pt) 2017-04-24
KR101376895B1 (ko) 2014-03-25
US8703181B2 (en) 2014-04-22
ES2616047T3 (es) 2017-06-09
CA2821167C (en) 2016-06-28
NL300885I2 (nl) 2022-02-24
NO2021004I1 (no) 2021-01-22
CA2566007A1 (en) 2005-11-17
RU2006142766A (ru) 2008-06-20
US10413510B2 (en) 2019-09-17
HK1200694A1 (en) 2015-08-14
LUC00026I1 (pl) 2017-07-11
AU2005240131A1 (en) 2005-11-17
HUS2500005I1 (hu) 2025-02-28
JP2014055172A (ja) 2014-03-27
AU2005240131C1 (en) 2014-05-08
RU2015155368A (ru) 2017-06-28
US20180169014A1 (en) 2018-06-21
US8147867B2 (en) 2012-04-03
US20160339014A1 (en) 2016-11-24
US20120171283A1 (en) 2012-07-05
EP1746976A1 (en) 2007-01-31
RU2015155368A3 (pl) 2019-08-19
US20180235954A1 (en) 2018-08-23
US20160106672A1 (en) 2016-04-21
EP4218730B1 (en) 2023-11-01
KR20140000348A (ko) 2014-01-02
LTPA2025504I1 (pl) 2025-02-10
CA2928387A1 (en) 2005-11-17
US20140154298A1 (en) 2014-06-05
CN1980637B (zh) 2014-02-19
KR20070036055A (ko) 2007-04-02
EP3173073B1 (en) 2024-11-06
TWI359029B (en) 2012-03-01
NL300885I1 (pl) 2017-07-19
KR101223366B1 (ko) 2013-01-16
CY2025003I2 (el) 2025-07-04
US8329213B2 (en) 2012-12-11
KR20120082039A (ko) 2012-07-20
US8992970B2 (en) 2015-03-31
US10722508B2 (en) 2020-07-28
US20150182460A1 (en) 2015-07-02
US20160030341A1 (en) 2016-02-04
US11052079B2 (en) 2021-07-06
NO345218B1 (no) 2020-11-09
US20170340624A1 (en) 2017-11-30
HUE068934T2 (hu) 2025-02-28
US20210137914A1 (en) 2021-05-13
CA2566007C (en) 2013-09-24
US20230181567A1 (en) 2023-06-15
JP2012092119A (ja) 2012-05-17
CA2821167A1 (en) 2005-11-17
CN103948545B (zh) 2017-10-03
JP4971142B2 (ja) 2012-07-11
US20160095817A1 (en) 2016-04-07
US9782349B2 (en) 2017-10-10
US20070116753A1 (en) 2007-05-24
LT3173073T (lt) 2025-01-10
US20170071858A1 (en) 2017-03-16
RU2757110C2 (ru) 2021-10-11
CN107811971A (zh) 2018-03-20
JP5502842B2 (ja) 2014-05-28
US9724303B2 (en) 2017-08-08
ES2967961T3 (es) 2024-05-06

Similar Documents

Publication Publication Date Title
PL1746976T3 (pl) Liposomy przydatne w systemie podawania leków
DE502004010609D1 (de) Transportroller
DE502004010027D1 (de) Mahlwalze
DE502004004375D1 (de) Wäschetrockner
EP1663544A4 (en) COMPOSITE STEERING RACK
FR2859943B1 (fr) Structure composite
PL1836825T3 (pl) Usprawnianie wczesnych mediów w systemie komunikacji
FI20041641L (fi) Sovitelma silmänpainemittarissa
FI20031304A0 (fi) Kuivauslaite
EP1809805A4 (en) DRYER
ITVI20040236A1 (it) Essiccatoio per filati avvolti in rocche
DE502005005356D1 (de) Tripode-rolle
ATA3402004A (de) Kunstleder
FI20050186L (fi) Kannatus staattorissa
FI20021365A0 (fi) Imutela
ITMO20040305A1 (it) Apparato pulitore
ATE491849T1 (de) Verbund
FI20045499A0 (fi) Järjestely oskillointilaitteessa
FIU20030484U0 (fi) Patukka-ateria
FI20041304A0 (fi) Termotela
ATA142004A (de) Drucklufttrockner
ES1059138Y (es) Maquina recreativa
FI20040423A0 (fi) Järjestely hississä
FIU20030026U0 (fi) Telajärjestely
FIU20050035U0 (fi) Pikalukitsin